New drug ABBV-313 takes first step in human safety trial
NCT ID NCT07673120
First seen Jun 29, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This early-stage trial is testing a new drug called ABBV-313 in healthy adult volunteers. The main goal is to check if the drug is safe and how the body handles it, including how it is absorbed and broken down. Participants receive either the drug or a placebo as an injection or infusion. This study does not aim to treat any disease but is a necessary first step before testing ABBV-313 in people with a specific condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABBV-313
- What this could lead to
- If successful, this study could provide the safety data needed to move ABBV-313 into future trials for specific diseases.
- What could go wrong
- This is a very early phase 1 study in healthy volunteers, so it cannot show whether the drug works for any disease. Side effects are possible and will be closely monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Acpru /Id# 283495
RECRUITINGGrayslake, Illinois, 60030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults